Table 1.
Background information of enrolled subjects
| Variables | pSS (n = 11) | Non‐SS (n = 5) | P‐value |
|---|---|---|---|
| Age (years), median (IQR) | 61 (57–65) | 52 (40–68) | 0·65a |
| Female, n (%) | 11 (100%) | 5 (100%) | 1b |
| Xerostomia, n (%) | 10 (90·9%) | 3 (60%) | 0·21b |
| Xerophthalmia, n (%) | 6 (54·5%) | 3 (60%) | 1b |
| Schirmer test positivity, n (%) | 4 (36·4%) | 2 (40%) | 0·84b |
| Saxon test positivity, n (%) | 9 (81·8%) | 3 (60%) | 0·35b |
| Anti‐SS‐A/Ro antibody positivity, n (%) | 11 (100%) | 0 (0%) | <0·001b |
| Anti‐SS‐B/La antibody positivity, n (%) | 4 (36·3%) | 0 (0%) | 0·12b |
| ANA positivity, n (%) | 11 (100%) | 0 (0%) | <0·001b |
| RF positivity, n (%) | 7 (63·6%) | 4 (80%) | 0·51b |
| Serum IgG, mg/dl, median (IQR) | 2140 (1550–2550) | 1047 (656–1246) | 0·009a |
| LSG biopsy, focus score | 6·9 (4–19·2) | 0 | 0·0019a |
| ESSDAI score, median (IQR) | 6 (4–6) | n.a. | n.a. |
P‐values < 0·05 were considered significant.
Non‐SS = these subjects were classified as non‐SS sicca control subjects based on the American–European Consensus Group (AECG) classification criteria.
ANA = anti‐nuclear antibody; ESSDAI = European League Against Rheumatism Sjögren's Syndrome Disease Activity Index; IgG = immunoglobulin G; IQR = interquartile range; LSG = labial salivary gland; n.a. = not assessed; pSS = primary Sjögren's syndrome; RF = rheumatoid factor.
a
Mann–Whitney U‐test.
b
Fisher's exact test.